{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 63/80', 'Certain:', 'Time relationship to IMP intake is plausible. Cannot be explained by concomitant disease', 'or other drugs. Response to withdrawal is plausible (pharmacologically, pathologically).', 'Event definitive pharmacologically or phenomenologically (i.e. an objective and specific', 'medical disorder or a recognized pharmacological phenomenon). Rechallenge', 'satisfactory, if ethical and necessary.', 'It should be emphasized that ineffective treatment (worsening of the disease) should not be', 'considered as causally related in the context of AE reporting.', '9.2.2. Assessment of Severity', 'The severity of AEs should be graded using the CTCAE version 5.0. If a CTCAE criterion does', 'not exist, the investigator should use the grade or adjectives: Grade 1 (mild), Grade 2', '(moderate), Grade 3 (severe), Grade 4 (life-threatening) or Grade 5 (fatal) to describe the', 'maximum intensity of the AE. For purposes of consistency with the CTCAE, these intensity', 'grades are defined in the table below.', 'Table 2', 'Grading of Adverse Event Severity', 'Grade', 'Adjective', 'Description', 'Grade 1', 'Mild', 'Asymptomatic or mild symptoms; clinical or diagnostic observations only;', 'intervention not indicated', 'Grade 2', 'Moderate', 'Local or noninvasive intervention indicated; limiting age-appropriate', 'instrumental ADL*', 'Grade 3', 'Severe', 'Severe or medically significant but not immediately life-threatening;', 'hospitalization or prolongation of hospitalization indicated; disabling;', 'limiting self-care ADL*', 'Grade 4', 'Life-threatening', 'Urgent intervention indicated', 'Grade 5', 'Death', 'Death-related AE', '*', 'Activities of Daily Living (ADL) Instrumental ADL refer to preparing meals, shopping for groceries or', 'clothes, using the telephone, managing money, etc.', '**', 'Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking', 'medications, and not bedridden.', 'For AEs associated with laboratory abnormalities, the event should be graded on the basis of', 'the clinical severity in the context of the underlying conditions; this may or may not be in', \"agreement with the grading of the laboratory abnormality. This is upon the investigator's\", 'assessment.', 'If there is a change in intensity (worsening or improvement) of an AE, it must be recorded.', '9.2.3. Outcome', 'Each AE must be rated by choosing among:', '- Recovered/resolved', '-', 'Recovered/resolved with sequelae.', '- Recovering/resolving.', '-', 'Not recovered/not resolved.', '-', 'Fatal.', '- Unknown.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 64/80', '9.3.', 'INVESTIGATOR REQUIREMENTS AND INSTRUCTIONS FOR', 'REPORTING ADVERSE EVENTS, SERIOUS ADVERSE', 'EVENTS, PREGNANCIES, AND OTHER SPECIAL', 'SITUATIONS TO THE SPONSOR', '9.3.1. Adverse Events', 'The AE reporting period for safety surveillance begins when the subject signs the ICF and ends', \"at the subject's last follow-up visit (the last follow-up visit after the last dose of IMP) as\", 'described in the Schedule of Activities (see Section 6.11). In this period, all new AEs, regardless', 'of cause or relationship, derived by spontaneous, unsolicited reports of subjects, by observation', 'and by routine open questioning (such as \"How do you feel?\") need to be recorded in the source', 'and in the CRF.', 'In case an AE is ongoing at the time of the last follow-up visit, the investigator needs to follow', \"on the subject until AE resolution or reasonable stabilization and to document in the subject's\", 'source documentation. No related updates or additional data on the AE should be reported in', 'the CRF.', 'If a subject is documented as lost-to-follow-up, ongoing/unknown outcome AEs will not be', 'followed up.', 'If the AE meets the criteria for seriousness, the SAE form must be completed and sent to the', 'sponsor within 24 hours (see Section 9.3.2).', '9.3.2. Serious Adverse Events', 'Subjects experiencing an SAE or an emergency situation will be examined by a physician as', 'soon as possible. The subject will remain under observation as long as medically indicated.', 'Appropriate laboratory tests will be performed until all parameters return to normal or are', 'otherwise explained or stable.', 'All SAEs, whether or not deemed IMP-related, must be recorded in the CRF and on the SAE', 'form. The investigator must report each SAE immediately, and under no circumstances should', 'this exceed 24 hours following the knowledge of the SAE, as is indicated on page 2 under', '\"Emergency Contact Information\".', 'The SAE form should at least contain identifiers of the subject and the reporter, SAE term and', 'statement of relatedness to the IMP, and at a later stage if not yet available within 24 hours, the', 'form needs to be completed with a clearly written narrative describing signs, symptoms, and', 'treatment of the event, diagnostic procedures, as well as any relevant laboratory data and any', 'sequelae.', 'Follow-up and outcomes should be reported and documented in the source documents for all', 'subjects that experience an SAE. It is important that the information provided on the SAE form', 'matches the information recorded on the CRF for the same event.', 'Copies of additional laboratory tests, consultation reports, postmortem reports, hospital case', 'reports, autopsy reports, and other documents should be sent when requested and available.', 'Only subject identifiers (subject number) should appear on the copies, and all names and initials', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}